Condition
Pantothenate Kinase-Associated Neurodegeneration
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
133%
4 of 3 completed with results
Key Signals
4 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 3 (3)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04182763Not ApplicableCompletedPrimary
CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)
NCT02635841UnknownPrimary
Compassionate Use of Deferiprone in Patients With PKAN
NCT03041116Phase 3TerminatedPrimary
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
NCT02174848Phase 3CompletedPrimary
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
NCT01741532Phase 3CompletedPrimary
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
Showing all 5 trials